A2BCD: a concise guide for asthma management

Lancet Respir Med. 2023 Jun;11(6):573-576. doi: 10.1016/S2213-2600(22)00490-8. Epub 2023 Jan 27.

Abstract

The management of asthma has changed fundamentally during the past two decades. Precise assessment and phenotyping are now required to establish individually targeted treatment with disease-modifying anti-asthmatic drugs (DMAADs). Patients with asthma are often managed by primary care doctors or non-respiratory specialists in secondary care. However, the implementation of complex asthma guidelines in non-specialised care remains a challenge. There is a need for easy-to-understand, concise guides for general practice. In this Viewpoint, we propose a one-page practical guide for asthma management, titled A2BCD, with four components: dual assessment (A2) of asthma (ie, diagnosis and phenotype, plus asthma control and future risks); basic measures (B; eg, education, self-management skills, regular physical activity, and avoidance of asthma triggers); identification and treatment of comorbidities (C) of asthma (eg, chronic rhinosinusitis, obesity, or sleep apnoea); and phenotype-specific, individually targeted treatment with DMAADs (D), including individual inhalation schemes based on inhaled corticosteroids, leukotriene modifiers, biologics, and allergen immunotherapy.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones
  • Anti-Asthmatic Agents*
  • Asthma* / chemically induced
  • Asthma* / diagnosis
  • Asthma* / therapy
  • Chronic Disease
  • Humans

Substances

  • Anti-Asthmatic Agents
  • Adrenal Cortex Hormones